Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

This new FDA-approved shot is designed to break down the barriers that have kept too many people from accessing PrEP.

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

The Food and Drug Administration on Wednesday approved a powerful new drug that provides almost complete protection against HIV infections. The twice-yearly injection, known as lenacapavir, offers ...

The U.S. has just approved a powerful new weapon in the fight against HIV: a twice-a-year prevention shot called Yeztugo. Made by Gilead Sciences, the injectable treatment slashes the risk ...

This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.

"This really has the possibility of ending HIV transmission," said Greg Millett, public policy director at The Foundation for AIDS Research.

The hotly anticipated results are in from a landmark pair of major clinical trials of a long-acting, injectable HIV-prevention drug that only requires dosing every six months. They are sensational ...

A federal judge in Texas ruled against a mandate requiring employers to provide coverage for PrEP drugs, which prevent the transmission of HIV.

Although the Food and Drug Administration approved the use of PrEP to prevent HIV in 2012, insurance coverage was slow to build and faced regional disparities, primarily in the South.

Learn more about this drug that can ward off HIV infection, including who should take it, side effects, and more.